Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ABUS with free AI briefings, catalyst countdowns, and dilution alerts.

ABUS · Arbutus Biopharma Corp

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$337.5M Cash on Hand
CF+ Cash Runway
Follow ABUS by email Get an email when ABUS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ABUS, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
AB-729 Chronic Hepatitis b Phase 2 · NCT04980482 Completed
ARB-001467 Hepatitis B, Chronic Phase 2 · NCT02631096 Completed
Imdusiran Hepatitis B, Chronic Phase 2 · NCT06245291 Withdrawn
Peg-IFNα-2a Chronic Hepatitis b Phase 2 · NCT04980482 Completed
Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1 Cancer Phase 1/2 · NCT01262235 Completed
Vebicorvir Chronic Hepatitis B Phase 2 · NCT04820686 Terminated
Umbilical Cord Blood-derived CD16-expressing… Chronic Hepatitis b Phase 1 · NCT05960240 Completed
AB-836 Chronic Hepatitis Phase 1 · NCT04775797 Terminated
Nucleos(t)ide Analogue Chronic Hepatitis b Phase 1 · NCT05960240 Completed
PRO-040201 Hypercholesterolemia Phase 1 · NCT00927459 Terminated
TKM-100201 Ebola Virus Infection Phase 1 · NCT01518881 Terminated
TKM-100802 for Injection Ebola Virus Infection Phase 1 · NCT02041715 Terminated

Also used in these trials (approved or third-party drugs, not ABUS's own candidates): Durvalumab, Entecavir.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ABUS holds $337.5M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ABUS files for a raise →

👥 Who Owns ABUS

Insiders 47.5% Institutions (263 holders) 52.5% Public and other holders 0%
HolderTypeShares% of sharesAs of
Matthew Gline
Director, 10% owner
Insider 38,847,462 25.34% 2025-02-24
Roivant Sciences Ltd.
Director, 10% owner
Insider 29,880,079 19.49% 2026-10-01
Morgan Stanley Institution (13G, 5%+) 18,682,708 12.19% 2026-09-30
NOMURA HOLDINGS INC Institution (13G, 5%+) 14,512,000 9.47% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 14,331,732 9.35% 2026-09-30
Michael J. McElhaugh
Interim President & CEO, Director · +718,800 options
Insider 1,658,003 1.08% 2025-02-14
Michael J. Sofia
Chief Scientific Officer · +437,800 options
Insider 1,652,283 1.08% 2024-02-01
David C Hastings
Chief Financial Officer · +815,800 options
Insider 249,824 0.16% 2025-02-14
Karen Sims
Chief Medical Officer · +604,200 options
Insider 155,494 0.10% 2025-02-14
J. Christopher Naftzger
General Counsel and CCO · +600,800 options
Insider 140,544 0.09% 2025-02-14
Tuan Nguyen
Chief Financial Officer · +1.40M options
Insider 111,882 0.07% 2026-10-01
Lindsay Androski
President and CEO, Director · +255,258 options
Insider 47,682 0.03% 2026-10-01

Share count 153,292,826 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ABUS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABUS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.